Hanmi Rollbedon, US 1Q Sales $15.6M... 54% Growth Compared to Previous Quarter

Secured 172 Clients... 145% Increase Compared to Last Year

Hanmi Pharm's neutropenia treatment 'Rolvedon,' sold locally in the United States, recorded sales of over 20 billion KRW in the first quarter of this year.

Hanmi Pharm Rolbedon. [Image provided by Hanmi Pharm]

Hanmi Pharm announced on the 15th that its partner Spectrum reported net sales of $15.6 million (approximately 20.6 billion KRW) for Rolvedon sold in the U.S., marking a 54% increase compared to the previous quarter.

Additionally, the number of Rolvedon purchasing clients and sales/distribution networks increased from 70 in the fourth quarter of last year to 172 in the first quarter of this year, showing a growth rate of 145%. Since last month, Rolvedon has been listed on the U.S. public insurance reimbursement drug list with the permanent J-code 'J1449' applied, creating a stable prescription environment.

Spectrum also reiterated in this earnings announcement that it has signed a merger agreement with Assertio, a specialized pharmaceutical company in non-face-to-face sales marketing that provides products to patients using digital platforms. The merger process between the two companies is expected to be completed by the third quarter.

Tom Lee, President of Spectrum, said, "By combining Spectrum's commercial infrastructure with Assertio's digital resources, we can establish a foundation for long-term growth, and we expect Rolvedon's revenue to increase more rapidly."

This content was produced with the assistance of AI translation services.